News for CPhI

New import laws spur hopes for reduced trial start-up time in Ukraine

By Natalie Morrison

- Last updated on GMT

New import laws spur hopes for reduced trial start-up time in Ukraine
Ukraine hopes changes to import laws will help cut trial start-up time from six month to 45 days.

Business development director for Ukraine firm Clinical Trail Logistics (CTL) Aleksey Mykheev told CPhI attendees that importing clinical investigational products now involves just two or three documents. Three years ago, the standard was 10.

He told Outsourcing-Pharma.com: “The legal system is being actively modernised. In 2012 customs legislation was significantly simplified and unified with European laws. As a result the number of customs procedures was reduced.”

With the new possibility for an electronic submission, he added, the customs process is much simpler.

“The Ukraine regulatory authority is expecting start-up phase, including supply of initial investigational product sites will decrease to 45 days,”​ Mykheev added.

He also said that with the possibility of eliminated clinical logistics VAT on imports until 2013 because of further expected updates to customs procedure, the Ukraine is becoming an increasingly popular destination for clinical trials.

However

Mykheev said however a stumbling block for many sponsors and logistics firms is a lack of knowledge about a new requirement, which stipulates all suppliers must first sign an agreement with the local site before importing investigational product.

“It is very important for sponsors and logistics companies to know this,”​ he said.

He also said recent Ministry of Health (MoH) updates could delay the streamlines imports process significantly because it now requires written permission and a good manufacturing practice (GMP) certificate with each batch. Previously the documentation was only required per shipment.

When asked how expectations of 45-day start-up time can happen in the face of the new regulation, he admitted: “It’s difficult to say if it will happen because the updated regulations have only been affective for three months.”

He added however that the local industry remains positive, and continues to expect significant growth over the next five years.

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers